Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NATALIZUMAB Cause Diffuse large b-cell lymphoma? 21 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 21 reports of Diffuse large b-cell lymphoma have been filed in association with NATALIZUMAB (TYRUKO). This represents 0.0% of all adverse event reports for NATALIZUMAB.

21
Reports of Diffuse large b-cell lymphoma with NATALIZUMAB
0.0%
of all NATALIZUMAB reports
4
Deaths
9
Hospitalizations

How Dangerous Is Diffuse large b-cell lymphoma From NATALIZUMAB?

Of the 21 reports, 4 (19.0%) resulted in death, 9 (42.9%) required hospitalization, and 2 (9.5%) were considered life-threatening.

Is Diffuse large b-cell lymphoma Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NATALIZUMAB. However, 21 reports have been filed with the FAERS database.

What Other Side Effects Does NATALIZUMAB Cause?

Multiple sclerosis relapse (6,478) Fatigue (4,456) Multiple sclerosis (4,078) Memory impairment (3,024) Malaise (2,523) Fall (2,481) Headache (2,476) Gait disturbance (2,427) Prescribed underdose (2,162) Maternal exposure during pregnancy (1,948)

What Other Drugs Cause Diffuse large b-cell lymphoma?

RITUXIMAB (1,571) CYCLOPHOSPHAMIDE (1,183) PREDNISONE (1,062) METHOTREXATE (1,055) VINCRISTINE (1,043) DOXORUBICIN (1,002) LENALIDOMIDE (779) TACROLIMUS (595) DEXAMETHASONE (539) PREDNISOLONE (506)

Which NATALIZUMAB Alternatives Have Lower Diffuse large b-cell lymphoma Risk?

NATALIZUMAB vs NATALIZUMAB-SZTN NATALIZUMAB vs NATAMYCIN NATALIZUMAB vs NATEGLINIDE NATALIZUMAB vs NAVITOCLAX NATALIZUMAB vs NAXITAMAB-GQGK

Related Pages

NATALIZUMAB Full Profile All Diffuse large b-cell lymphoma Reports All Drugs Causing Diffuse large b-cell lymphoma NATALIZUMAB Demographics